MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Pfizer General and Administrative Expenses 2011-2026 | PFE
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Pfizer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.8 B | 14.7 B | 14.8 B | 13.7 B | 12.7 B | 11.6 B | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.8 B | 11.6 B | 13.5 B |
Quarterly General and Administrative Expenses Pfizer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.19 B | 3.42 B | 3.03 B | 3.24 B | 3.72 B | 3.5 B | 3.28 B | 3.5 B | 3.42 B | - | 3.39 B | 3.05 B | 2.59 B | - | 2.9 B | 2.92 B | 2.78 B | - | 2.66 B | 2.66 B | 2.54 B | - | 3.26 B | 3.51 B | 3.34 B | - | 3.49 B | 3.54 B | 3.41 B | - | 3.5 B | 3.43 B | 3.32 B | - | 3.56 B | 3.47 B | 3.38 B | - | 3.27 B | 3.39 B | 3.1 B | - | 3.56 B | 3.52 B | 3.04 B | - | 3.4 B | 3.59 B | 3.22 B | - | 3.49 B | 3.66 B | 3.97 B | - | 4.46 B | 4.97 B | 4.5 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.97 B | 2.54 B | 3.38 B |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
965 B | $ 18.06 | - | $ 28.2 B |  Japan |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 19.44 | -0.46 % | $ 909 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | USA |
 |
Protara Therapeutics
TARA
|
21.9 M | $ 5.03 | -3.08 % | $ 215 M | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Tarsus Pharmaceuticals
TARS
|
427 M | $ 67.0 | -0.3 % | $ 2.8 B | USA |
 |
bluebird bio
BLUE
|
166 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Theravance Biopharma
TBPH
|
73.7 M | $ 14.9 | -1.91 % | $ 750 M |  Cayman-islands |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.2 | -6.97 % | $ 306 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B | Cayman-islands |
 |
Bio-Techne Corporation
TECH
|
589 M | $ 51.31 | -2.65 % | $ 8.08 B | USA |
 |
Tenax Therapeutics
TENX
|
23.7 M | $ 14.64 | -2.2 % | $ 574 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
27.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
78.9 M | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
232 K | $ 1.07 | -2.29 % | $ 21.9 M | Israel |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.29 B | $ 28.76 | -3.43 % | $ 32.9 B | Israel |
 |
Enochian Biosciences
ENOB
|
17.9 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
10.8 M | $ 2.03 | -1.46 % | $ 116 M | USA |
 |
Eton Pharmaceuticals
ETON
|
35.8 M | $ 23.81 | 1.51 % | $ 641 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
73.5 M | $ 46.38 | -2.45 % | $ 4.17 B |  Schweiz |